Melatonin in antinociception: Its therapeutic applications

Current Neuropharmacology

Volumn 10, Issue 2, 2012, Pages 167-178

  Srinivasan, Venkatramanujam ^a   Lauterbach, Edward C ^b   Ho, Khek Yu ^c   Acuña Castroviejo, Dario ^d   Zakaria, Rahimah ^e   Brzezinski, Amnon ^f  

^a Sri Sathya Sai Medical Educational and Research Foundation   (India)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d UNIVERSITY OF GRANADA   (Spain)

^e SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Analgesia; Cluster headache; Fibromyalgia; Inflammatory; Melatonin; Migraine; Neuropathic; Nociception; Pain

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ATROPINE; BENZODIAZEPINE RECEPTOR; BETA ENDORPHIN; CAPSAICIN; FLUMAZENIL; GRAPE SEED PROANTHOCYANIDIN; HARPAGOPHYTUM PROCUMBENS EXTRACT; HYPERICUM PERFORATUM EXTRACT; LIPOPOLYSACCHARIDE; LUZINDOLE; MECAMYLAMINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; N1 ACETYL N2 FORMYL 5 METHOXY KYNURAMINE; N2 ACETYL 5 METHOXY KYNURAMINE; NALOXONE; NICOTINIC RECEPTOR; NORADRENALIN; OPIATE; OPIATE RECEPTOR; PRAZOSIN; PROANTHOCYANIDIN DERIVATIVE; SEROTONIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; ARTICLE; CEREBROSPINAL FLUID; CIRCADIAN RHYTHM; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; EVIDENCE BASED MEDICINE; HARPAGOPHYTUM; HORMONE SYNTHESIS; HUMAN; HYPERALGESIA; HYPERICUM PERFORATUM; HYPOTHALAMUS; INFLAMMATION; LIVER; NEUROMODULATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PAIN THRESHOLD; PATHOPHYSIOLOGY; PAW EDEMA; TAIL FLICK TEST;

EID: 84861748819     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912800604489     Document Type: Article

References (135)

1. Bonica, J.J. The need of a taxonomy of pain. Pain, 1979, 6, 247-248.
2. Costigan, M., Woolf, C.J. Pain: molecular mechanisms. J. Pain, 2000, 1, 35-44.
3. Jarvis, M.F., Boyce-Rustay, J.M. Neuropathic pain: models and mechanisms. Curr. Pharm. Des., 2009, 15, 1711-1716.
4. Fishbain, D.A., Cutler, R., Rossomoff, H.L., Rossomoff, R.S. Chronic-pain associated depression: antecedent or consequence of chronic pain. A review. Clin. J. Pain, 1997, 13, 116-137.
5. Blackburn-Munro, G., Blackburn-Munro, R. Chronic pain, chronic stress and depression: coincidence or consequence? Are hormones to blame? J. Neuroendocrinol., 2001, 13, 1009-1023.
6. Stahl, S.M. Does depression hurt? J. Clin. Psychiatry, 2002, 63, 273-274.
7. Stahl, S.M. Fibromuyalgia-pathways and neurotransmitters. Hum. Psychopharmacol., 2009, 24, S11-S17.
8. Shavali, S., Ho, B., Govitrpong, P., Sawlom, S., Ajjimaporn, A., Klongpanichapak, S., Ebadi, M. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of β endorphin an endogenous opioid. Brain Res. Bull., 2005, 64, 471-479.
9. Meyer, R.A., Ringkamp, M., Campbell, J.N., Raja, S.N. Peripheral mechanisms of cutaneous nociception. In: Text Book of Pain, McMahon, S., Koltzenburg, M., Eds.; Wall and Melzack 5th Ed: Elsevier, London, 2005, pp 3-34.
10. Riedel, W., Neeck, G. Nociception, pain, and antinociceptive mechanisms. J. Rheumatol., 2001, 60, 404-415.
11. Pace, M.C., Mazzariello, L., Passavanti, M.B., Sansone, P., Barbarisi, M., Aurillo, C. Neurobiology of pain. J. Cell Physiol., 2006, 209, 8-12.
12. Vanderah, T.W. Pathophysiology of pain. Med. Clin. North Am., 2007, 91, 1-12.
13. Cury, Y., Picolo, G., Guiterrez, V.P., Ferreira, S.H. Pain and analgesia: The dual effect of nitric oxide in the nociceptive system. Nitric Oxide, 2011, 25(3), 243-254.
14. Ferreira, S.H. Prostaglandins, aspirin like drugs, and analgesia. Nat. New Biol., 1972, 240, 200-203.
15. Duarte, L.D., Lorenzetti, B.B., Ferreira, S.H. Peripheral analgesia and activation of the nitric-oxide-cyclic GMP pathway. Eur. J. Pharmacol., 1990, 186, 289-293.
16. Foley, K.M. Clinical tolerance to opioids. In: Toward a new pharmacology of pain, Bausmam, A.I., Besson, J.M., Eds.; Wiley: Chichester, 1991, pp. 181-204.
17. Pasternak, G.W. When it comes to opiates, just say NO. J. Clin. Invest., 2007, 117, 3185-3187.
18. Ford, B. Pain in Parkinson's disease. Mov. Disord., 2010, 25 (suppl 1), S98-S103.
19. Reichling, D.B., Levine, J.D. Pain and death: neurodegenerative disease, mechanisms in the nociceptor. Ann. Neurol., 2011, 69(1), 13-21.
20. MacFarlane, B.V., Wright, A., O'Callaghan, J., Benson, H.A.E. Chronic neuropathic pain and its control by drugs. Pharmacol., Ther., 1997, 75, 1-19.
21. Woolf, C.J., Mannion, R.J. Neuropathic pain: etiology, symptoms and mechanisms, and management. Lancet, 1999, 353, 1959-1964.
22. Watson, C.P. The treatment of neuropathic pain: antidepressants and opioids. Clin. J. Pain, 2000, 16, S49-S55.
23. Crockett, R.S., Bornchein, R.L., Smith, R.P. Diurnal variations in response to thermal stimulation: mouse-hot plate test. Physiol. Behav., 1977, 18(2), 193-196
24. Davis, G.C., Buschbaum, M.S., Bunney, W.E. Jr. Naloxone decreases diurnal variation in pain sensitivity and somatosensory evoked potentials. Life Sci., 1978, 23, 1449-1460.
25. Pollmann, L., Harris, P.H. Rhythmic changes in pain sensitivity in teeth. Int. J. Chronobiol., 1978, 5(3), 459-464.
26. Laikin, M.I., Miller, C.H., Stott, M.L., Winters, W.D. Involvement of the pineal gland and melatonin in murine analgesia. Life Sci., 1981, 29, 2543-2551.
27. Brzezinski, A. Melatonin in humans. N. Engl. J. Med., 1997, 336, 186-195.
28. Klein, D.C., Weller, J.I., Moore, R.Y. Melatonin meysabolism: neural regulation of pineal serotonin, acetyl coenzyme A. Nacetyl transferase activity. Proc. Natl. Acad. Sci. U.S.A., 1971, 68, 3107-3110.
29. Klein, D.C., Schaad, N.L., Namboodiri, M.A., Yu, L., Weller, J.L. Regulation of pineal serotonin-N-acetyl transferase activity. Biochem. Soc. Trans., 1992, 20, 299-304.
30. Berson, D.M. Phototransduction in ganglion-cell photoreceptors. Pflugers Arch., 2007, 454, 849-855.
31. Moore, R.Y. Neural control of the pineal gland. Behav. Brain Res., 1996, 73, 125-130.
32. Schomerus, C., Korf, H.W. Mechanisms regulating melatonin biosynthesis in the mammalian pineal organ. Ann. N. Y. Acad. Sci., 2005, 1057, 372-383.
33. Klein, D.C. Arylalkylamine-N-acetyltransferase, "time enzyme". J. Biol. Chem., 2007, 282, 4233-4237.
34. Tricoire, H., Moller, M., Chemineau, P., Malpaux, B. Origin of cerebrospinal fluid melatonin and its possible function in the integration of photoperiod. Reprod. Suppl., 2003, 61, 311-321.
35. Reppert, S.M., Perlow, M.J., Tamarkin, L., Klein,.D.C. A diurnal melatonin rhythm in primate cerebrospinal fluid. Endocrinology, 1979, 104(2), 295-301.
36. Reiter, R.J., Tan, D.X. Role of CSF in the transport of melatonin. J. Pineal Res., 2002, 33, 61.
37. Hirata, F., Hayaishi, O., Tokuyama, T., Seno, S. In vitro and in vivo formation of two metabolites of melatonin. J. Biol. Chem., 1974, 249, 1311-1313.
38. 2-formyl-5-methoxy kynuramine, a biogenic amine and melatonin metabolite, functions as a potent oxidant. FASEB J., 2001, 15, 2294-2296.
39. Slominsky, A., Fischer, T.W., Zmijewski, M.A., Wortsman, J., Semak, I., Zbytek, B., Slominski, R.M., Tobib, T.J. On the role of melatonin in skin physiology and pathology. Endocrine, 2005, 27, 137-148.
40. Carrillo-Vico, A., Calvo, J.R., Abreu, P., Lardone, P.J., Garcia-Maurino, S., Reiter, R.J., Guerrero, JM. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J., 2004, 18, 537-539.
41. Naranjo, M.C., Guerrero, J.M., Rubio, A., Lardone, P.J., Carrillo-Vico, A., Carrascosca-salmoral, M.P., Jimenez-Jorge, S., Arellano, M.V., Leal-Novel, S.R., Leal, M., Lissen, E., Molinero, P. Melatonin biosynthesis in the thymus of humans and rats. Cell Mol. Life Sci., 2007, 64, 781-790.
42. Esposito, E., Paterniti, I., Mazzon, E., Bramant, P., Cuzzocrea, S. Melatonin reduces hyperalgesia associated with inflammation. J. Pineal Res., 2010, 49, 321-331.
43. Murch, S.J., Simmons, C.B., Sazena, P.K. Melatonin in fever few and other medicinal plants. Lancet, 1997, 350, 1598-1599.
44. Murch, S. J, Krishnaraj, S., Saxena, P.K. Tryptophan is a precursor for melatonin and serotonin biosynthesis in vitro regenerated St John's wort (Hypericum perforatum L. cv. Anthos) plants. Plant Cell Reports, 2000, 19, 698-704.
45. Uchida, S., Hirai, K., Hatanaka, J., Hanato, J., Umegaki, K., Yamada, S. Antinociceptive effects of St. John's wort, Harpagophytum Procumbens extract and Grape seed Proanthocyanidins extract in mice. Biol. Pharm. Bull., 2008, 31(2), 240-245.
46. Chen, G., Huo, Y., Tan, D.X., Liang, Z., Zhang, W., Zhang, Y. Melatonin in Chinese medicinal herbs. Life Sci., 2003, 73, 19-26.
47. Hardeland, R., Fuhrberg, B. Ubiquitous melatonin. Presence and effects in unicells, plants and animals. Trends Comp. Biochem. Physiol., 1996, 2, 25-45.
48. Kolar, J., Machakova, I. Melatonin in higher plants: occurrence and possible functions. J. Pineal Res., 2005, 39, 333-341.
49. Hardeland, R., Pandi-Perumal, S.R. Melatonin, a potent agent in anti-oxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nut. Metab. (Lond.), 2005, 2, 22.
50. Pandi-Perumal, S.R., Srinivasan, V., Maestroni, G.J.M., Cardinali, D.P., Poeggeler, B., Hardeland, R. Melatonin, nature's versatile biological signal. FEBS J., 2006, 273, 2813-2838.
51. Reppert, S.M., Weaver, D.R., Ebisawa, T. Cloning and characeterization of a mammalian receptor that mediates reproductive and circadian responses. Neuron, 1994, 13, 1177-1185.
52. Reppert, S.M., Godson, C., Mahle, C.D., Weaver, D.R., Slaugenhaupt, S.A., Gusella, J.F. Molecular characterization of a second melatonin receptor expressed in human retina and brain. The Mel1b receptor. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 8734-8738.
53. Dubocovich, M.L., Markowska, M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine, 2005, 27, 101-110.
54. Acuña-Castroviejo, D., Reiter, R.J., Menéndez Peláez, A., Pablos, M.I., Burgos, A. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J. Pineal Res., 1994, 16, 100-112.
55. Beckser-Andre, M., Wiesenberg, I., Schaeren-Wiemers, N., Andre, E., Missbach, M., Saurat, J.H., Calberg, C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem., 1994, 269(46), 28531-28534.
56. Zahn, P.K., Lansmann, T., Berger, E., Speckmann, E.J., Musshoff, U. Gene expression and functional characterization of melatonin receptors in the spinal cord of the rat: implications for pain modulation. J. Pineal Res., 2003, 35(1), 24-31.
57. Weaver, D.R., Rivkees, S.A., Reppert, S.M. Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. J. Neurosci., 1989, 99(7), 2581-2590.
58. Williams, L.M., Hannah, L.T., Hastings, M.H., Maywood, E.S. Melatonin receptors in the rat brain and pituitary. J. Pineal Res., 1995, 19(4), 173-177.
59. Srinivasan, V., Pandi-Perumal, S.R., Spence, D.W., Moscovitch, A., Trakht, I., Brown, G.M., Cardinali, D.P. Potential use of melatonergic drugs in analgesia. Brain Res. Bull., 2010, 81, 362-371.
60. Golombek, D.A., Escolar, E., Burin, L.J., Bristo-Sanchez, M.G., Cardinali, D.P. Time dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism. Eur. J. Pharmacol., 1991, 194, 25-30.
61. Gomar, M.D., Fernández, B., Castillo, J.L., Del Aguila, C.M., Acuña-Castroviejo, D. Melatonin counteracts pinealectomy-dependent decreases in rat brain [3H]flunitrazepam binding through an opioid mechanism. Neurosci Lett., 1993, 164(1-2), 149-153.
62. Yu, C.X., Zhu, C.B., Xu, S.F., Cao, X.D., Wu, G.C. The analgesic effects of peripheral and central administration of melatonin in rats. Eur. J. Pharmacol., 2000, 403, 49-53.
63. Li, S.R., Wang, T., Wang, X., Dai, X., Chen, Q., Li, R.D. Melatonin enhances anti-nociceptive effects of δ but not μ opioid agonist in mice. Brain Res., 2005, 1043(1-2), 132-138.
64. Raghavendra, V., Agrewala, J.N., Kulkarni, S.K. Melatonin reversal of lipo-polysaccharides induced thermal and behavioural hyperalgesia in mice. Eur. J. Pharmacol., 2000, 395(1), 15-21.
65. El-Shenawy, S.M., Abdel-Salam, O.M., Baiuomy, A.R., ELBatran, S., Arbid, M.S. Studies on the inflammatory and antinociceptive effect of melatonin in the rat. Pharmacol. Res., 2002, 46(3), 235-243.
66. Cuzzocrea, S., Costantino, G., Mazzon, E., Caputi, A.P. Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin. J. Pineal Res., 1999, 27(12), 9-14.
67. Elmegeed, G.A., Baiuomy, A.R., Abdel-Salam, O.M. Evaluation of the anti-inflammatory and anti-nociceptive activities of the novel synthesized melatonin analogues. Eur. J. Med. Chem., 2007, 42(10), 1285-1292.
68. Mantovani, M., Pertile, R., Calixto, J.B., Santos, A.R., Rodriguez, A.L. Melatonin exerts its antidepressant like effect in the tail suspension test in mice: evidence for involvement of N-methyl-daspartate receptors and the L-arginine nitric oxide pathway. Neurosci. Lett., 2003, 343(1), 1-4.
69. Tu, Y., Sun, R.Q., Willis, W.D. Effects of intrathecal injections of melatonin analogs on capsaicin-induced seconday allodynia and hyperalgesia in rats. Pain, 2004, 109, 340-350.
70. Ray, M., Mediratta, P.K., Mahajan, P., Sharma, K.K. Evaluation of the role of melatonin in formalin induced pain response in pain. Ind. J. Med. Sci., 2004, 58(3), 122-130.
71. Hernandez-Pacheo, A., Araiza-Saldana, C.I., Grandos-Soto, V., Mixcoatlzecuati, T. Possible participation of the nitric oxide-cyclic GMP protein kinase GK+ channels pathway in the peripheral antinociception of melatonin. Eur. J. Pharmacol., 2008, 596, 70-76.
72. Yoon, M.H., Park, H.C., Kim, W.M., Lee, H.G., Kim, Y.O., Huang, L.J. Evaluation for the interaction between intrathecal melatonin and clonidine or neostigmine on formalin-induced nociception. Life Sci., 2008, 83, 845-850.
73. Shin, D.J., Jeong, C.W., Lee, S.H., Yoon, M.H. Receptors involved in antinociception of intrathecal melatonin in formalin test of rats. Neurosci. Lett., 2011, 494, 207-210.
74. Billici, D., Akpiner, E., Kiziltuic, A. Protective effective of melatonin in carageenen induced acute local inflammation. Pharmacol. Res., 2002, 46, 133-139.
75. Naguib, M.C., Hammond, D.L., Schmid III, P.G., Baker, M.T., Cutkomp, J., Queral, L., Smith, T. Pharmacological effects of intravenous melatonin: comparative studies with thiopental and propofol. Br. J. Anesthesiol., 2003, 90, 504-507.
76. Naguib, M.C., Baker, M.T., Spadoni, G., Gregerson, M. The hypnotic and analgesic effects of bromomelatonin. Anesth. Analg., 2003, 97, 763-768.
77. Seltzer, Z., Dubner, R., Shir, Y. A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain, 1990, 43, 205-218.
78. Seltzer, Z. The relevance of animal neuropathy models of chronic pain in humans. Neurosciences, 1995, 7, 211-219.
79. Malmberg, A.B., Basbaum, A.I. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioural and neuroanatomical correlates. Pain, 1998, 76, 215-222.
80. Ulugol, A., Dokmeci, D., Guray, G., Sapolyo, N., Ozyigit, F., Tamer, M. Anti-hyperalgesic but not antiallodynic effect of melatonin in nerve injured neuropathic mice: possible involvements of the L-arginine-NO-pathway and opioid system. Life Sci., 2006, 78, 1592-1597.
81. Ambriz-Tututi, M., Granodos-Soto, V. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain, 2007, 132(3), 273-280.
82. Zhou, H.Y., Chen, S.R., Pan, H.L. Treating N-methyl-D-aspartate receptors for treating neuropathic pain. Expert Rev. Clin. Pharmacol., 2011, 4(3), 379-388.
83. Brenner, R., Azbel, V., Madhusoodhanan, S., Pawlowska, M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double blind randomized pilot study. Clin. Ther., 2000, 22, 411-419.
84. Chatterjee, S., Bhattacharya, S.K., Wonnemann, M., Singer, A., Muller, W.E. Hyperforin as a possible antidepressant component of hypercium extracts. Life Sci., 1998, 63, 499-510.
85. Singer, A., Wonnemann, M., Muller, W.E. Hyperforin, a major antidepressant constituent of St John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J. Pharmacol. Exp. Ther., 1999, 290, 1363-1368.
86. Yoshitake, T., Iizuka, R., Yoshitake, S., Weikop, P., Müller, W.E., Ögren, S.O., Kehr, J. (Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. Br. J. Pharmacol., 2004, 142(3), 414-418.
87. Woolf, C.J. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann. Int. Med., 2004, 140(6), 441-451.
88. Defrin, R., Ginzburg, K., Solomon., Polad, E., Block, M., Covezensky, M., Schreiber, S.l. Quantitative testing of pain perception in subjects with PTSD-implications for the mechanism of the coexistence between PTSD and chronic pain. Pain, 2008, 138, 450-459.
89. Schmahl, C., Meinzer, M., Zeuch, A., Fichter, M., Cebulla, M., Kleindienst, N., Ludäscher, P., Steil, R., Bohus, M. Pain sensitivity is reduced in borderline personality disorders, but not in posttraumatic stress disorder and bulimia nervosa. World J. Biol. Psychiatry, 2008, 29, 1-8.
90. Lepin, J.P., Briley, M. The epidemiology of pain in depression. Hum. Psychopharmacol., 2004, 19(Suppl 1), S3-S7.
91. Briley, M. New hopes in the treatment of painful symptoms of depression. Curr. Opin. Invest. Drugs, 2003, 4, 42-45.
92. Delgado, P.L. Common pathways of depression and pain. J. Clin. Psychiatry, 2009, 65, 16-19.
93. Robinson, M.J., Edwards, S.E., Iyengar, S., Bymaster, F., Clark, M., Katon, W. Depression and pain. Front. Biosci., 2009, 14, 5031-5051.
94. Wall, P.D., Melzack, R. Text Book of Pain (5th Edn.); Churchill & Livingstone New York, 2005.
95. Stahl, S.M. Stahl's Essential Psychopharmacology (3rd Edn.); Cambridge University Press, Cambridge, 2008.
96. Benedetti, F., Vighetti, S., Amanzio, M., Casadio, C., Oliaro, A., Bergamasco, B., Maggi, G. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain, 1998, 74(2-3), 205-211.
97. Fornaro, M., Prestia, D., Colicchio, S., Perugi, G. A systemic updated review on the antidepressant agomelatine: focussing on its melatonergic modulation. Curr. Neuropharmacol., 2010, 8, 287-304.
98. Kennedy, S.H., Rizvi, S.J. Agomelatine in the Treatment of Major Depressive Disorder: Potential for clinical effectiveness. CNS Drugs, 2010, 24, 479-499.
99. Srinivasan, V., Brzezinski, A., Spence, D.W., Pandi-Perumal, S.R., Hardeland, R., Brown, G.M., Cardinali, D.P. Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy of treatment. Psychiatrica Fennica, 2010, 41, 168-187.
100. de Beradis, D., Di Lorio, G., Aciavatti, T., Conti, C., Serroni, N., Olivieri, L., Cavuto, M., Martinotti, G., Janiri, L., Moschetta, F.S., Conti, P., Di giannantono, M. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol. Disord. Drug Target, 2011, 10, 119-132.
101. Neumann, L., Buskila, D. Epidemiology of fibromyalgia. Cur. Pain Headache Rep., 2003, 7, 362-368.
102. Clauw, D.J., Crofford, L.J. Chronic widespread pain and fibromyalgia: what we know and what we do not know. Best Pract. Res. Clin. Rheumatol., 2003, 17, 685-701.
103. Mease, P.J. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J. Rheumatol., 2005, 75, 6-21.
104. Arnold, L.M., Hudson, J.I., Keck, P.E. Jr., Auchenbach, M.B., Javaras, K.N., Hess, E.V. Comorbidity of fibromyalgia and psychiatric disorders. J. Clin. Psychiatry, 2006, 67, 1219-1225.
105. Bennett, R.M. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin. Proc., 1999, 74, 385-398.
106. Bennett, R. Fibromyalgia: present to future. Curr. Rheumatol. Rep., 2005, 7, 371-376.
107. Gracely, R.H., Petzke, F., Wolf, J.M., Clauw, D.J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum., 2002, 46, 1333-1343.
108. Staud, R., Rodriguez, M.E. Mechanisms of disease: pain in fibromyalgia syndrome. Nat. Clin. Pract., 2006, 2, 90-98.
109. Wikner, J., Hirsch, U., Wetterberg, L., Rojdmark, S. Fibromyalgia-a syndrome associated with decreased nocturnal melatonin secretion. Clin. Endocrinol. (Oxf)., 1998, 49(2), 179-183.
110. Citera, G., Arias, M.A., Maldonado-Cocco, J.A., Lazaro, M.A., Rosemfett, M.G., Brusco, L.I., Scheines, E.J., Cardinali, D.P. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin. Rheumatol., 2000, 19, 9-13.
111. Hussain, S.A., Al-Khalifa, H., Jasim, N.A., Gorial, F.I. Adjuavant use of melatonin for treatment of fibromyalgia. J. Pineal Res., 2011, 50, 267-271.
112. Acuña-Castroviejo, D., Escames, G., Reiter, R.J. Melatonin therapy for fibromyalgia. J. Pineal Res., 2006, 40(1), 98-99.
113. Reiter, R.J., Acuna-Castroviejo, D., Tan, D.X. Melatonin therapy for fibromyalgia. Curr. Pain Headache Rep., 2007, 11, 339-342.
114. Song, G.H., Leng, P.H., Gwee, K.A., Moochhala, S.M., Ho, K.Y. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomized, double-blind, placebo controlled study. Gut, 2005, 54, 1402-1407.
115. Lu, W.Z., Gwee, K.A., Moochhalla, S., Ho, Y.Y. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double blind placebo controlled study. Aliment. Pharmacol. Ther., 2005, 22, 927-934.
116. Brun, J., Claustrat, B., Saddier, P., Chazot, G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with means. Cephalagia, 1995, 15, 136-139.
117. Masruha, M.R., de Souza Viera, D.S., Minett, T.S., Cipolla-Neto, J., Zuckerman, E., Vilanova, L.C., Peres, M.F. Low urinary 6-sulphatoxy-melatonin concentrations in acute migraine. J. Headache Pain, 2008, 9, 221-234.
118. Claustrat, B., Brun. J., Geoffriau, M., Zaidan, R., Malloc, C., Chazot, G. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephaligia, 1997, 17, 511-517.
119. Tabeeva, G.R., Sergeev, A.V. Gromova, S.A. Possibilities of preventive treatment of migraine with MT1 and MT2 agonist and 5-HT2c receptor antagonist agomelatin (valdoxan). Zh. Neurol. Psikhiatr. Im., 2011, 111(9), 32-36.
120. May, A., Bahra, A., Buchel, C., Frackowiak, R.S., Goadsby, P.J. Hypothalamic activation in cluster headache attacks. Lancet, 1998, 352, 275-278.
121. Chazot, G., Claustrat, B., Brun, J., Jordon, D., Sassolas, G., Schott, B. A chrono-biological study of melatonin, cortisol, growth hormone, and prolactin secretion in cluster headache attacks. Cephaligia, 1984, 4, 213-220.
122. Leone, M., D'Amico, D., Moschiano, F., Fraschini, F., Bussone, G. Melatonin versus placebo in the prophylaxis of cluster headache: a double blind pilot study with parallel groups. Cephalagia, 1996, 21, 494-496.
123. Peres, M.F.P., Rozen, T.D. Melatonin in the preventive treatment of chronic cluster headache. Cephalagia, 2001, 21, 993-995.
124. Peres, M.F.P. Melatonin, the pineal gland and their implications for headache. Cephalagia, 2005, 25, 403-411.
125. Tanuri, F.C., delima, E., Peres, M.F., Caabral, F.R., da grace, Naffah-Mazzacoratti, M., Cavalheiro, E.A., Cipolla-Neto, J., Zukerman, E., Amado, D. Melatonin treatment decreases c-fos expression in a headache model induced by capsaicin. J. Headache Pain, 2009, 10, 105-110.
126. Mantovani, M., Kaster, M.P., Pertile, R., Calixto, J.B., Rodriguez, A.L., Santos, A.R. Mechanisms involved in the antinociception caused by melatonin in the mice. J. Pineal Res., 2006, 41, 382-389.
127. Schmidtko, A., Tegeder, I., Geisslinger, G. No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci., 2009, 32, 339-346.
128. Laurido, C., Pelissie, T., Soto-Mayono, R., Valladares, L., Flores, F., Hernandez, A. Effect of melatonin on rat spinal cord nociceptive transmission. Neuroreport, 2002, 13, 89-91.
129. Zhang, Y., Quock, L.P., Chung, E., Ohgami, Y., Quock, R.M. Involvement of a NO-cyclic GMP-PKG signalling pathway in a nitrous oxide-induced antinociception in mice. Eur. J. Pharmacol., 2011, 654, 249-253.
130. Ambriz-Tututi, M., Rocha-Gonzalez, H.I., Cruz, S.L., Granados-Soto, V. Melatonin: A hormone that modulates pain. Life Sci., 2009, 84, 489-498.
131. Onal, S.A., Inalkac, S., Kutlu, S., Kelestimur, H. Intrathecal melatonin increases the mechanical nociceptive threshold in the rat. Agriculture, 2004, 16, 35-40.
132. Arreola-Espino, R., Urquiza-Marín, H., Ambriz-Tututi, M., Araiza-Saldaña, C.I., Caram-Salas, N.L., Rocha-González, H.I., Mixcoatl-Zecuatl, T., Granados-Soto, V. Melatonin reduces formalininduced nociception and tactile allodynia in diabetic rats. Eur. J. Pharmacol., 2007, 577(1-3), 203-210.
133. Mickle, A., Sood, M., Zhang, Z., Shahmohammadi, G., Sengupta, J.N., Miranda, A. Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: A centrally mediated process. Pain, 2010, 149, 555-564.
134. Ismail, S.A., Mowafii, H.A. Melatonin provides anxiolysis, enhances analgesia, decreases intra ocular pressure and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth. Analg., 2009, 108, 1146-1151.
135. Mowafii, H.A., Ismail, S.A. Melatonin improves Tourniquet tolerance and enhances postoperative analgesia in patients receiving intravenous regional anesthesia. Anesth. Analg., 2008, 107, 1422-1426.